Serina Therapeutics, Inc.(SER) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights Operating expenses: Operating expenses for the three months ended June 30, 2025 and 2024 were $5.7 million and $3.9 million, respectively. • Advancement of SER-270 for Tardive Dyskinesia: In July 2025, Serina announced the advancement of SER-270 (POZ- VMAT2i), a once-weekly injectable therapy for tardive dyskinesia (TD), enabled by the POZ Platform. The program aims to address unment needs in TD t ...